Douglas Adkins, MD

Medical Oncologist

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine

Clinical Expertise

Head and neck cancer

Research Interest

Evaluation of targeted therapy approaches in patients with head and neck squamous cell carcinoma. Participation on multi-institutional trials of therapy for soft tissue and bone sarcomas.

Education

1986: MD, Wright State University, Dayton, Ohio

Training

1986 - 1989: Intern and resident, internal medicine, University of Texas Health Science Center, San Antonio
1989 - 1990: Fellow, medical oncology/hematology, University of Texas Health Science Center, San Antonio
1990 - 1992: Fellow, bone marrow transplantation, University of Texas Health Science Center, San Antonio

Board Certification

1990, 2000: American Board of Internal Medicine, Internal Medicine
1993, 2003: American Board of Internal Medicine, Medical Oncology

Selected Research Publications

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.

Smith AE, Chan S, Wang Z, [...] Adkins DR, [...] Malik S
Cancer Res 2023

Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer.

Cotto KC, Feng YY, Ramu A, [...] Adkins D, [...] Griffith M
Nat Commun 2023

Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).

Ho AL, Foster NR, Zoroufy AJ, [...] Adkins D, [...] Schwartz GK
J Clin Oncol 2022

Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.

Adkins DR, Haddad RI
Cancer Treat Rev 2022

The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell Carcinoma.

Adkins D, Ley J, Cohen J, Oppelt P
Cancer J 2022

Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.

Taylor MH, Betts CB, Maloney L, [...] Adkins D, [...] Coussens LM
Clin Cancer Res 2022

NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022.

Caudell JJ, Gillison ML, Maghami E, [...] Adkins D, [...] Darlow SD
J Natl Compr Canc Netw 2022

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.

Subbiah V, Hu MI, Wirth LJ, [...] Adkins D, [...] Taylor MH
Lancet Diabetes Endocrinol 2021

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.

Sacco AG, Chen R, Worden FP, [...] Adkins D, [...] Cohen EEW
Lancet Oncol 2021

Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.

Mudianto T, Campbell KM, Webb J, [...] Adkins DR, [...] Uppaluri R
Clin Cancer Res 2021

Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.

Adkins DR, Lin JC, Sacco A, [...] Tahara M
Oral Oncol 2021

Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial.

Adkins D, Ley J, Atiq O, [...] Oppelt P
Oral Oncol 2021

nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial.

Oppelt P, Ley J, Daly M, [...] Adkins D
Med Oncol 2021

Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial.

Oppelt P, Ley JC, Worden F, [...] Adkins D
Oral Oncol 2021

Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma.

Van Tine BA, Weiss MC, Hirbe AC, [...] Adkins DR
Rare Tumors 2021

Contact Information

Washington University Medical Campus

4921 Parkview Place
Saint Louis, MO 63110

Phone Numbers

Appointments: (314) 747-7222
Toll Free: (800) 600-3606

Request an appointment